文献速递脊柱关节炎

Tildrakizumab治疗活动性银屑病关节炎的52周IIb期研究

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
PubMed 文献 · Ann Rheum Dis · 2021-05-13

这项随机双盲安慰剂对照IIb期研究纳入391例活动性银屑病关节炎患者,评估tildrakizumab(抗IL-23p19单抗)的疗效与安全性。第24周时,tildrakizumab组71.4%–79.5%患者达ACR20,显著高于安慰剂组的50.6%(均p<0.01),但未观察到指炎和附着点炎的改善;治疗总体耐受良好。

要点

  • 第24周ACR20应答率tildrakizumab组71.4%–79.5%,安慰剂组50.6%,均p<0.01。
  • 未观察到指炎和附着点炎改善,其他结局结果不一。
  • 截至第52周,TEAE发生率64.5%,严重TEAE发生率3.3%,各组间相当。

核心结论

  • Tildrakizumab可显著改善银屑病关节炎的关节和皮肤表现,但指炎和附着点炎未见改善。
  • 治疗至第52周总体耐受良好。

研究设计与样本

  • 随机、双盲、安慰剂对照、多剂量IIb期研究,500例筛查患者中391例随机并接受治疗。
  • 患者按1:1:1:1:1随机接受tildrakizumab 200 mg每4周、200/100/20 mg每12周或安慰剂每4周。
  • 第24周时tildrakizumab 20 mg组和安慰剂组换用tildrakizumab 200 mg每12周,治疗持续至第52周。
  • 主要疗效终点为第24周ACR20应答率。

主要发现

  • 第24周,tildrakizumab组71.4%–79.5%患者达ACR20,安慰剂组为50.6%(所有p<0.01)。
  • 第24周及至第52周,tildrakizumab组ACR50、DAS28-CRP<3.2、最小疾病活动度及PASI 75%/90%/100%应答率普遍高于安慰剂组。
  • 未观察到指炎和附着点炎改善,其他结局结果不一。
  • 第24周换用tildrakizumab 200 mg的患者应答与从基线开始治疗者一致。
  • 截至第52周,所有患者TEAE和严重TEAE发生率分别为64.5%和3.3%,各治疗组间相当。

关键数值与推荐

  • 主要疗效终点:第24周ACR20应答率,tildrakizumab组71.4%–79.5% vs 安慰剂组50.6%(所有p<0.01)。
  • 次要疗效终点未进行多重性校正。
  • 安全性评估采用治疗中出现的不良事件(TEAE)。

临床怎么用

  • Tildrakizumab可作为改善银屑病关节炎关节和皮肤表现的治疗选择之一。
  • 对指炎和附着点炎患者,不应期待tildrakizumab带来明确改善。
  • 治疗期间需关注TEAE,严重TEAE发生率约3.3%。

局限性

  • 次要疗效终点未进行多重性校正。
  • 指炎和附着点炎未观察到改善,其他结局结果不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). METHODS: In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active PsA were randomised 1:1:1:1:1 to tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab 200, 100 or 20 mg Q12W; or placebo Q4W. Patients receiving tildrakizumab 20 mg or placebo switched to tildrakizumab 200 mg Q12W at W24; treatment continued to W52. The primary efficacy endpoint was proportion of patients with ACR20 response (≥20% improvement by American College of Rheumatology criteria) at W24. Secondary efficacy endpoints were assessed without adjustment for multiplicity. Safety was evaluated from treatment-emergent adverse events (TEAEs). RESULTS: 391/500 patients screened were randomised and treated. At W24, 71.4%-79.5% of tildrakizumab-treated versus 50.6% of placebo-treated patients achieved ACR20 (all p<0.01). Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52. Improvement in dactylitis and enthesitis was not observed; results were mixed for other outcomes. Responses in patients switched to tildrakizumab 200 mg at W24 were consistent with treatment from baseline. TEAEs and serious TEAEs occurred in 64.5% and 3.3%, respectively, of all patients through W52 and were comparable among treatment arms. CONCLUSIONS: Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment was generally well tolerated through W52. Clinicaltrials.gov NCT02980692.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021. PMID: 33985942. doi:10.1136/annrheumdis-2020-219014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。